Abstract
Intellia Therapeutics has acquired Rewrite Therapeutics, a developer of DNA-writing technologies, for $45 million plus $155 million in potential milestone payments. Intellia is developing gene-editing therapies based on the CRISPR-Cas9 editing system. The company says Rewrite’s DNA-writing tools, including CRISPR-Cas9-guided polymerases, could provide new ways to edit disease-causing genes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
